Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank88
5Y CAGR-42.2%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-42.2%/yr
Long-term compound
Percentile
P88
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 3.95% |
| 2024 | -19.46% |
| 2023 | -91.01% |
| 2022 | -67.64% |
| 2021 | -124.34% |
| 2020 | 61.01% |
| 2019 | -149.25% |
| 2018 | 0.09% |
| 2017 | 0.00% |